Table 1. The total 41 risk sets for the example data (taken from Appendix D in reference 10).
Ordered Risk Set | Failure Time | Number of Subjects At Risk | Risk Factor Status for the Relapsed Patients | |||
---|---|---|---|---|---|---|
(j) | (Days) | n 11j | n 10j | n 01j | n 00j | (CMV a , MTX b ) |
1 | 32 | 26 | 40 | 12 | 55 | (0,0) |
2 | 47 | 25 | 40 | 12 | 54 | (0,0) and (0,0) |
3 | 48 | 25 | 40 | 12 | 52 | (0,0) |
4 | 55 | 24 | 39 | 12 | 51 | (1,1) |
5 | 64 | 23 | 39 | 11 | 51 | (1,1) |
6 | 74 | 22 | 39 | 11 | 51 | (1,1) |
7 | 76 | 20 | 39 | 11 | 51 | (1,1) |
8 | 84 | 19 | 39 | 10 | 49 | (1,0) |
9 | 93 | 18 | 38 | 10 | 49 | (1,0) |
10 | 100 | 18 | 37 | 10 | 49 | (1,0) |
11 | 104 | 18 | 36 | 10 | 49 | (0,0) |
12 | 109 | 17 | 35 | 10 | 47 | (1,1) |
13 | 110 | 16 | 35 | 10 | 47 | (1,1) |
14 | 113 | 15 | 35 | 10 | 47 | (1,1) |
15 | 115 | 14 | 35 | 10 | 47 | (1,0) |
16 | 120 | 14 | 34 | 10 | 47 | (1,0) |
17 | 122 | 14 | 33 | 10 | 47 | (1,1) |
18 | 129 | 13 | 33 | 10 | 46 | (0,1) |
19 | 157 | 13 | 33 | 9 | 46 | (1,0) |
20 | 192 | 12 | 32 | 9 | 42 | (1,1) |
21 | 211 | 11 | 32 | 9 | 41 | (0,0) |
22 | 219 | 11 | 32 | 9 | 40 | (1,1) |
23 | 230 | 10 | 32 | 9 | 39 | (0,0) |
24 | 242 | 10 | 32 | 9 | 38 | (0,0) |
25 | 248 | 10 | 32 | 9 | 37 | (0,0) |
26 | 268 | 10 | 32 | 9 | 36 | (1,0) |
27 | 272 | 10 | 31 | 9 | 36 | (1,0) |
28 | 273 | 10 | 30 | 9 | 36 | (1,1) |
29 | 381 | 8 | 28 | 8 | 35 | (0,0) |
30 | 383 | 8 | 28 | 8 | 34 | (0,0) |
31 | 390 | 8 | 28 | 8 | 33 | (1,0) |
32 | 421 | 8 | 27 | 8 | 30 | (0,0) |
33 | 422 | 8 | 27 | 8 | 29 | (0,0) |
34 | 456 | 8 | 27 | 8 | 28 | (1,0) |
35 | 467 | 8 | 26 | 7 | 28 | (1,0) |
36 | 486 | 8 | 24 | 7 | 28 | (0,0) |
37 | 606 | 8 | 24 | 6 | 25 | (1,1) |
38 | 609 | 7 | 24 | 6 | 25 | (1,0) |
39 | 625 | 7 | 23 | 6 | 25 | (1,0) |
40 | 662 | 7 | 22 | 6 | 24 | (0,0) |
41 | 748 | 7 | 20 | 6 | 23 | (0,0) |
a Cytomegalovirus immune status: 1 if CMV positive, and 0 if otherwise.
b Methotrexate usage: 1 if MTX being used, and 0 if otherwise.